ライフサイエンスコーパス: early-stage breast cancer

1 ACH]: Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer).

2 ease after initially successful treatment of early stage breast cancer.

3 ed with doxorubicin plus cyclophosphamide in early stage breast cancer.

4 r arising in patients previously treated for early stage breast cancer.

5 cterize clinically relevant heterogeneity in early stage breast cancer.

6 ortality among women with previously treated early stage breast cancer.

7 e initial adjustment of women diagnosed with early stage breast cancer.

8 sulted in improved survival of patients with early stage breast cancer.

9 local radiotherapy after primary surgery for early-stage breast cancer.

10 and medical expenditures among patients with early-stage breast cancer.

11 vant chemotherapy regimens are available for early-stage breast cancer.

12 adjuvant trastuzumab use in older women with early-stage breast cancer.

13 O-1 expression and metastatic progression in early-stage breast cancer.

14 al growth factor receptor 2 (HER2) -positive early-stage breast cancer.

15 for women age >/= 70 years with ER-positive early-stage breast cancer.

16 have proven benefit as adjuvant therapy for early-stage breast cancer.

17 otherapy in a population of older women with early-stage breast cancer.

18 to neoadjuvant chemotherapy in patients with early-stage breast cancer.

19 ction in women treated with chemotherapy for early-stage breast cancer.

20 2 years, standard deviation: 6.2 years) with early-stage breast cancer.

21 e response among patients with HER2-negative early-stage breast cancer.

22 identified women 67 to 94 years of age with early-stage breast cancer.

23 tes of recurrence and death in patients with early-stage breast cancer.

24 side effects than tamoxifen in patients with early-stage breast cancer.

25 t from adjuvant trastuzumab in patients with early-stage breast cancer.

26 ee and overall survival for older women with early-stage breast cancer.

27 irm the poorer prognosis of obese women with early-stage breast cancer.

28 abine in patients age 65 years or older with early-stage breast cancer.

29 eatment and experience higher mortality from early-stage breast cancer.

30 ith reduced overall survival in survivors of early-stage breast cancer.

31 extended letrozole therapy to patients with early-stage breast cancer.

32 vant treatment for postmenopausal women with early-stage breast cancer.

33 scribed as adjuvant therapy in patients with early-stage breast cancer.

34 in postmenopausal hormone receptor-positive early-stage breast cancer.

35 ognosis and treatment benefit for women with early-stage breast cancer.

36 ce with anastrozole therapy among women with early-stage breast cancer.

37 owledge of surgical therapy among women with early-stage breast cancer.

38 important adjuncts for counseling women with early-stage breast cancer.

39 adjustment after diagnosis and treatment for early-stage breast cancer.

40 of depressive symptoms in women treated for early-stage breast cancer.

41 estrogen receptor (ER) status in women with early-stage breast cancer.

42 vant treatment for postmenopausal women with early-stage breast cancer.

43 omy are definitive treatments for women with early-stage breast cancer.

44 ther developments in the adjuvant setting of early-stage breast cancer.

45 ausal women receiving adjuvant letrozole for early-stage breast cancer.

46 sk of fractures in postmenopausal women with early-stage breast cancer.

47 rvival in women who have been diagnosed with early-stage breast cancer.

48 ycles among women receiving chemotherapy for early-stage breast cancer.

49 event in a cohort of women with a history of early-stage breast cancer.

50 ase in the SLN and bone marrow of women with early-stage breast cancer.

51 e through February 2004 on the use of SNB in early-stage breast cancer.

52 CEGT does not prolong survival in women with early-stage breast cancer.

53 detected in BM aspirates from patients with early-stage breast cancer.

54 psilateral breast tumor recurrence (IBTR) in early-stage breast cancer.

55 epidermal growth factor receptor 2-positive early-stage breast cancer.

56 y does not adversely affect the prognosis of early-stage breast cancer.

57 ealth consensus statement recommendation for early-stage breast cancer.

58 stases in previously untreated patients with early-stage breast cancer.

59 and Cdk2 are suitable therapeutic targets in early-stage breast cancer.

60 y and tangential radiation therapy (TRT) for early-stage breast cancer.

61 ab in neoadjuvant treatment of HER2-positive early-stage breast cancer.

62 LE gain for young women with BRCA-associated early-stage breast cancer.

63 parison with doxorubicin-cyclophosphamide in early-stage breast cancer.

64 ease outcome in a large cohort of women with early-stage breast cancer.

65 sentinel node biopsy (SNB) for patients with early-stage breast cancer.

66 n CT decisions in patients with ER-positive, early-stage breast cancer.

67 ncer recurrence in hormone receptor-positive early-stage breast cancer.

68 mportant competing risk for older women with early-stage breast cancer.

69 ta on the risk of cardiovascular death after early-stage breast cancer.

70 elderly black and white women diagnosed with early-stage breast cancer.

71 y fitness in patients previously treated for early-stage breast cancer.

72 in the treatment of patients age >/= 65 with early-stage breast cancer.

73 tion of pathologic and molecular features in early-stage breast cancer.

74 mph nodes improves survival in patients with early-stage breast cancer.

75 prediction of clinical outcome in women with early-stage breast cancer.

76 standard therapy in patients with high-risk early-stage breast cancer.

77 surgery (BCS) in the majority of women with early-stage breast cancer.

78 survival (EFS) and overall survival (OS) in early-stage breast cancer.

79 ith node-positive or high-risk node-negative early-stage breast cancer.

80 ate-stage breast cancers as oppose to 13% in early-stage breast cancers.

81 o identify factors that predict diagnosis of early-stage breast cancers.

82 Three surgical options exist for early stage breast cancer: (1) breast conserving surgery

83 in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physici

84 n of paclitaxel as adjuvant chemotherapy for early-stage breast cancer, 9 months after presentation o

85 treatment at six New York City hospitals for early-stage breast cancer about their care, knowledge, a

86 Among survivors of early stage breast cancer, adoption of a diet that was v

87 gical (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocr

88 oglobin A1C (HbA1C) among 3,003 survivors of early-stage breast cancer (age of diagnosis, 28 to 70 ye

89 Early-stage breast cancer, age, cardiovascular disease,

90 uperior to those of placebo among women with early-stage breast cancer, although it resulted in more

91 ages (+/- SE) measured from the diagnosis of early-stage breast cancer among the 94 study group patie

92 ivalent to mastectomy for most patients with early-stage breast cancer, an increasing number of patie

93 phosphamide, in patients with HER2-amplified early stage breast cancer and examined whether this regi

94 rstone of adjuvant therapy for patients with early stage breast cancer and oestrogen-receptor-positiv

95 agement for a sizable fraction of women with early-stage breast cancer and appears to offer clinicall

96 , phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic r

97 evolutionised the treatment of HER2-positive early-stage breast cancer and is now standard of care in

98 itaxel is active against HER2 overexpressing early-stage breast cancer and may be feasible as part of

99 irradiation (WBI) for selected patients with early-stage breast cancer and permitted hypofractionated

100 aged 20 to 44 years who were diagnosed with early-stage breast cancer and received a CPM increased i

101 se of the widespread use of chemotherapy for early-stage breast cancer and the improved survival.

102 receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes

103 y in the underuse of adjuvant treatments for early-stage breast cancer and to identify associated fac

104 or older diagnosed with invasive unilateral early-stage breast cancer and treated with surgery from

105 ncluded AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain

106 inion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfactio

107 than tamoxifen by postmenopausal women with early-stage breast cancer, and results in fewer serious

108 breast cancer, adjuvant endocrine therapy in early-stage breast cancer, and salvage chemotherapy in a

109 tatus of the axillary nodes in patients with early-stage breast cancer, and SLN mapping is gaining wi

110 erapy in reducing mortality in patients with early stage breast cancer appears to be generalisable to

111 Individuals who receive chemotherapy for early-stage breast cancer are a select subgroup of patie

112 Some women with early-stage breast cancer are at higher risk of recurren

113 women treated for depression before primary early-stage breast cancer are at increased risk for rece

114 Depressive symptoms in women treated for early-stage breast cancer are not associated with object

115 Most patients with early-stage breast cancer are treated with adjuvant radi

116 Early-stage breast cancers are biologically heterogeneou

117 Women with early-stage breast cancers are expected to have excellen

118 Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity

119 ng vaginal ring (7.5 mug/d) in patients with early-stage breast cancer (BC) receiving an AI.

120 30 years and older who underwent surgery for early-stage breast cancer between 1983 and 1995.

121 med of 1,490 women diagnosed and treated for early-stage breast cancer between 1991 and 2000.

122 Medicare records for patients diagnosed with early-stage breast cancer between 2001 and 2007, tumor m

123 MarketScan database who were diagnosed with early-stage breast cancer between 2003 and 2007.

124 s conducted among 98999 women diagnosed with early-stage breast cancer between April 1, 1998, and Mar

125 ndomly assigned 455 women with HER2-positive early-stage breast cancer between January 5, 2008, and M

126 For early-stage breast cancer, breast conservation surgery (

127 ssed receipt of definitive local therapy for early-stage breast cancer by race/ethnicity and age and

128 d cohort (n=5439), the Nottingham historical early stage breast cancer cohort (Nottingham-HES; n=1650

129 In this large early-stage breast cancer cohort, MN risk after radiatio

130 red thirty-nine women previously treated for early-stage breast cancer completed surveys that present

131 of 49-year-old women with HER2/neu-positive early-stage breast cancer: conventional chemotherapy wit

132 breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-t

133 stantial increases in the number of cases of early-stage breast cancer detected, screening mammograph

134 le blood has potential as a novel method for early stage breast cancer detection, but there are still

135 Nearly 30% of women with early-stage breast cancer develop recurrent disease attr

136 women who had received standard therapy for early-stage breast cancer diagnosed between September 19

137 nt guidelines for the systemic management of early-stage breast cancer differ when applied to stage T

138 east cancer outcomes in women diagnosed with early-stage breast cancer differs on the basis of tumor

139 Approximately 20% of early-stage breast cancers display amplification or over

140 Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab-the

141 s from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and

142 Adult women diagnosed with early-stage breast cancer during 1990-2008 (n = 3,965) w

143 e quality of systemic therapy for women with early-stage breast cancer (EBC).

144 rogen receptor-positive, lymph node-negative early-stage breast cancer (EBC).

145 premenopausal women undergoing treatment for early-stage breast cancer (EBC).

146 e feasibility and cardiac safety of T-DM1 in early-stage breast cancer (EBC).

147 CAM use was high among patients with early-stage breast cancer enrolled in a multisite prospe

148 Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a

149 actice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incid

150 in selecting adjuvant therapy for women with early-stage breast cancer for endorsement.

151 ssemble a retrospective cohort of women with early-stage breast cancer from 2007 to 2010 who underwen

152 opausal women with hormone receptor-positive early-stage breast cancer from the ABCSG 8 and TransATAC

153 ng a prospective design, 6,211 patients with early-stage breast cancer from two large population-base

154 reventing recurrence and death in women with early-stage breast cancer, further efforts are necessary

155 Adjuvant chemotherapy in early stage breast cancer has been shown to reduce morta

156 study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically im

157 Although the prognosis for patients with early-stage breast cancer has improved, the therapeutic

158 erence to tamoxifen therapy among women with early-stage breast cancer has revealed adherence estimat

159 ical approach of the axilla in patients with early-stage breast cancer has witnessed considerable evo

160 curately staging the axilla in patients with early-stage breast cancer have become progressively less

161 Adjuvant treatments for early-stage breast cancer have been shown to improve hea

162 Minority women with early-stage breast cancer have double the risk of white

163 juvant anthracycline therapy in survivors of early-stage breast cancer have had limited study.

164 Outcomes for early-stage breast cancer have improved.

165 Many patients with early-stage breast cancer have treatment options and app

166 uvant radiation therapy in the management of early stage breast cancer, Hodgkin's disease, and to a l

167 native to whole-breast irradiation (WBI) for early-stage breast cancer; however, current national tre

168 onserving surgery increased among women with early-stage breast cancer in 14 US commercial health car

169 men, aged 20 years and older, diagnosed with early-stage breast cancer in 1987 to 1991, 1995, and 200

170 Treatment of early-stage breast cancer in HMOs often differs from loc

171 d 1,081 women (response, 70%) diagnosed with early-stage breast cancer in Massachusetts or Minnesota

172 priate care, the appropriateness of care for early-stage breast cancer in the USA declined from 1990

173 Management of early-stage breast cancer in young women with mutations

174 tasis or disease recurrence in patients with early-stage breast cancer, in this study, denosumab did

175 s performed of the records of 207 women with early-stage breast cancer (including five women with bil

176 of neoplastic progression for patients with early stage breast cancer, including ductal carcinoma in

177 ration of normal ductal epithelial cells and early-stage breast cancer invasion and stemness.

178 In patients with early-stage breast cancer, irradiation of the regional n

179 urance payer status on surgical treatment of early stage breast cancer is unclear.

180 ence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated mu

181 velopment of breast-conserving treatment for early-stage breast cancer is one of the most important s

182 n after surgery on survival among women with early-stage breast cancer is unknown.

183 f adjuvant radiation therapy, especially for early-stage breast cancer mandates long-term follow-up t

184 CT) is an accepted modality for treatment of early-stage breast cancer, many women continue to underg

185 erly black versus white women diagnosed with early-stage breast cancer; matching by tumor characteris

186 etiology of sporadic breast cancer, and that early-stage breast cancer may be intrinsically susceptib

187 A substantial proportion of women with early-stage breast cancer may be suboptimally adherent t

188 n other patients, suggesting that women with early-stage breast cancer may benefit from surgeons' eff

189 Evaluation of HSP90 expression in early-stage breast cancer may identify a subset of patie

190 Women diagnosed with early-stage breast cancer might improve overall prognosi

191 formance status of 1 or less; HER2-amplified early stage breast cancer; operable, histologically conf

192 For patients with early-stage breast cancer, our findings support whole-br

193 aoperative radiotherapy (IORT) in women with early stage breast cancer outside of a clinical trial, a

194 ng on whole blood could discriminate between early stage breast cancer patients and healthy controls.

195 y-based miRNA profiling on whole blood of 48 early stage breast cancer patients at diagnosis along wi

196 e differentially expressed in whole blood of early stage breast cancer patients compared to healthy c

197 -qPCR) validation in a separate cohort of 24 early stage breast cancer patients from a breast cancer

198 Early stage breast cancer patients, versus control women

199 he new standard of care for nodal staging in early-stage breast cancer patients and contraindications

200 ted genetic markers in BM aspirate plasma of early-stage breast cancer patients and provides a unique

201 etween oncologist adoption of paclitaxel for early-stage breast cancer patients and variables represe

202 Early-stage breast cancer patients completing medical tr

203 Early-stage breast cancer patients diagnosed from 1996 t

204 tive single-agent denosumab in premenopausal early-stage breast cancer patients from the Phase-II D-B

205 Non-recommended testing for early-stage breast cancer patients has decreased over ti

206 Observed rates of stroke in 820 eligible early-stage breast cancer patients treated at the Univer

207 er lumpectomy was prospectively evaluated in early-stage breast cancer patients treated with breast-c

208 ased physical activity (PA) intervention for early-stage breast cancer patients was evaluated in a ra

209 olled 24 predominantly white, well-educated, early-stage breast cancer patients who were facing local

210 ompared with surveillance alone, 30-year-old early-stage breast cancer patients with BRCA mutations g

211 Local-regional recurrences are rare in early-stage breast cancer patients with H&E-negative SLN

212 mary breast tumor gene expression from 1,378 early-stage breast cancer patients with long-term clinic

213 In early-stage breast cancer patients, a 10-week CBSM inter

214 s a potential marker of improved survival in early-stage breast cancer patients, independent of the s

215 Participants included 5569 early-stage breast cancer patients, treated with breast-

216 ylase resulted in a prolonged survival among early-stage breast cancer patients.

217 te occult disease in SLNs and bone marrow of early-stage breast cancer patients.

218 ic aspects of psychological well-being among early-stage breast cancer patients.

219 d having adopted paclitaxel for 37% of their early-stage breast cancer patients.

220 on in breast tumors derived from a cohort of early-stage breast cancer patients.

221 How women with early-stage breast cancer perceive the risks and benefit

222 d who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether

223 ate the MammaPrint assay in 6,693 women with early-stage breast cancer provided a signal.

224 d and 21.2% with hypofractionation-permitted early-stage breast cancer received hypofractionated WBI

225 mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherap

226 otypes and clinical outcome in patients with early-stage breast cancer receiving adjuvant tamoxifen.

227 Women with early-stage breast cancer receiving an AI who had a wors

228 blood counts were performed in 20 women with early-stage breast cancer receiving four courses of cycl

229 types with clinical outcome in patients with early-stage breast cancer receiving tamoxifen.

230 nal expression and benefit finding regarding early-stage breast cancer reduced medical visits for can

231 most effective adjuvant therapy regimen for early-stage breast cancer regardless of hormone receptor

232 herapy with radiation (RT) for patients with early-stage breast cancer remains uncertain.

233 Adjuvant RT in early-stage breast cancer significantly reduces in-breas

234 All patients had early-stage breast cancer (stages 0-II).

235 atients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after dia

236 equent CBC occurrence among older women with early-stage breast cancer, suggesting that preoperative

237 -3/CA 27.29 and associated Medicare costs in early-stage breast cancer survivors.

238 ible patients were postmenopausal women with early-stage breast cancer taking an AI for > 30 days wit

239 nd that a substantial fraction of women with early-stage breast cancer terminated their chemotherapy

240 7 women between the ages of 48 and 79 y with early-stage breast cancer tested the hypothesis that die

241 ed with a doubling in the number of cases of early-stage breast cancer that are detected each year, f

242 In early-stage breast cancer, the primary treatment option

243 nthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs n

244 recurrence and death among young women with early-stage breast cancer, they have not adequately addr

245 stasis) who had had local tumour excision of early stage breast cancer to receive 50 Gy radiotherapy

246 doxorubicin (A) and cyclophosphamide (C) in early-stage breast cancer to determine if administration

247 domly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyc

248 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxo

249 rial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or

250 rial randomized 455 women with HER2-positive early-stage breast cancer to trastuzumab, lapatinib, or

251 A retrospective review of 55 women with early-stage breast cancer treated from 1990 to 1995 was

252 onable management for selected patients with early-stage breast cancer treated with breast-conserving

253 Among women with early-stage breast cancer treated with lumpectomy and ra

254 n 2013, we classified patients with incident early-stage breast cancer treated with lumpectomy and WB

255 Among the 1224947 women with early-stage breast cancer treated with surgery, the prop

256 is procedure to a microarray data set of 286 early-stage breast cancers treated only with surgery and

257 Medical records from 2,327 women with early-stage breast cancer, treated at the M.D. Anderson

258 epidermal growth factor receptor 2-positive, early-stage breast cancer (Tykerb Evaluation After Chemo

259 ndomized clinical trial of 324 patients with early-stage breast cancer undergoing chemotherapy (cyclo

260 es, nearly half of young women with invasive early-stage breast cancer underwent a CPM from 2010 to 2

261 oral trends in performance of mastectomy for early-stage breast cancer using multivariable logistic r

262 dy of women receiving adjuvant treatment for early-stage breast cancer was conducted.

263 Early-stage breast cancer was defined as having a tumor

264 ath in black versus white men diagnosed with early-stage breast cancer was largely confined to those

265 rvival in a metacohort of 1006 patients with early-stage breast cancer, we identified 54 CRGs whose e

266 ll beta-chain repertoire in 16 patients with early-stage breast cancer, we show that the clonal struc

267 Most older women with early-stage breast cancer were adherent to short-term or

268 zed trial in which postmenopausal women with early-stage breast cancer were assigned to receive anast

269 ients who became pregnant after diagnosis of early-stage breast cancer were identified in institution

270 January 1993 and January 2000, 174 cases of early-stage breast cancer were managed with lumpectomy f

271 average, 2 years since primary treatment for early-stage breast cancer were randomly assigned to eith

272 cal trial in which postmenopausal women with early-stage breast cancer were randomly assigned to rece

273 One hundred sixty women with early-stage breast cancer were recruited from three trea

274 en (n = 288) undergoing adjuvant therapy for early-stage breast cancer were recruited from two outpat

275 he rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied

276 inically annotated, microarray data from 784 early-stage breast cancers were identified, and prospect

277 h in a contemporary population of women with early-stage breast cancer while accounting for competing

278 change in 3088 women previously treated for early stage breast cancer who were 18 to 70 years old at

279 is superior to capecitabine in patients with early-stage breast cancer who are 65 years of age or old

280 marker that may help identify patients with early-stage breast cancer who could benefit from more ag

281 Furthermore, patients with early-stage breast cancer who experienced cardiovascular

282 aged 18 years or older with newly diagnosed, early-stage breast cancer who had a definite indication

283 All 723 women with early-stage breast cancer who had a definitive surgical

284 Overweight or obese women with clinically early-stage breast cancer who had been assigned to under

285 Among women with newly diagnosed early-stage breast cancer who had been treated with stan

286 atients treated with breast conservation for early-stage breast cancer who subsequently underwent car

287 Proportion of women with early-stage breast cancer who underwent mastectomy.

288 Data from 1,021 nonpregnant women with early-stage breast cancer who underwent SLN mapping and

289 Among women with early-stage breast cancer who were at high clinical risk

290 Thirty-four young premenopausal women with early-stage breast cancer who were exposed to chemothera

291 We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant ch

292 In a follow-up study of 200 women with early-stage breast cancer who were treated with adjuvant

293 In this population of patients with early-stage breast cancer who were treated with adjuvant

294 ve to routine staging ALND for patients with early-stage breast cancer with clinically negative axill

295 f the treatment costs for elderly women with early-stage breast cancer, with emphasis on costs of mod

296 to include patients with large but operable early-stage breast cancer, with the possibility in some

297 Younger women (age < 51 years, N = 252) with early-stage breast cancer within 2 months of having comp

298 d acceptably accurate method for identifying early-stage breast cancer without involvement of the axi

299 ients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metas

300 onducted to test whether older patients with early-stage breast cancer would have equivalent relapse-